** Shares of Vertex Pharmaceuticals VRTX.O fall 5.04% to $475 premarket
** Co posted Q1 revenue of $2.77 billion, missing analyst estimates of $2.85 billion according to data compiled by LSEG
** Co raised the low end of its full-year 2025 revenue forecast range to $11.85 billion from $11.75, keeping the higher end at $12 billion
** Co saw a revenue decline in Russia where Vertex's intellectual property rights is being violated
** Street estimates may not have fully encompassed the previously disclosed impacts of an unauthorized copy of co's cystic fibrosis Trikafta in Russia - William Blair
** Reports quarterly adj profit of $4.06 per share, below estimates of $4.32
** Up to last close, stock down ~24% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.